Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab for prevention of cerebral vasospasm after subarachnoid hemorrhage
2009-017448-15Phase 2Terminated
- Sponsor
- Neuromed
- Start
- Dec 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of infliximab in subarachnoid hemorrhage (SAH) and cerebral vasospasm (2 arms), sponsored by Neuromed. Primary endpoints: Primary effectiveness endpoint and Safety endpoint. Started Dec 2009; status: terminated.
02
Drugs
infliximab
03
Conditions
subarachnoid hemorrhage (SAH)cerebral vasospasm
Beyond the preview
Go deeper on 2009-017448-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017448-15.